Skip to main content

Table 1 Baseline Characteristics of the EPIC Study

From: Prospective clinical trial of Intravitreal aflibercept treatment for PolypoIdal choroidal vasculopathy with hemorrhage or exudation (EPIC study): 6 month results

Characteristic

(N = 21)

Mean Age, Years (Range)

77 (59 – 91)

Males, N (%)

10 (48)

Ethnicity, N (%)

 Asian

19 (90)

 Caucasian

2 (10)

Laterality, N (%)

 Unilateral

16 (76)

 Bilateral

5 (24)

Prior Treatment, N (%)

 Prior Anti-VEGF

11 (52)

 Prior ML

1 (4)

 Prior PDT

1 (4)

 None (Treatment-Naïve)

10 (48)

Median Visual Acuity (Range)

20/40 (20/200 – 20/16)

Mean ETDRS Letters (Range)

65.7 (30 – 89)

Mean Central Foveal Thickness, (μM)

283 (164 – 550)

  1. VEGF vascular endothelial growth factor, ML macular laser, PDT Photodynamic therapy, ETDRS Early Treatment Diabetic Retinopathy Study, μm micrometers, n number